Form 4: KalVista Pharmaceuticals: CFO Piekos Reports Stock Transactions

KalVista Pharmaceuticals' Chief Financial Officer, Brian Piekos, has reported transactions involving restricted stock units and common stock.

Summary

• Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals, Inc., reported a transaction on May 21, 2026, where 5,000 restricted stock units (RSUs) were acquired.
• On May 22, 2026, Piekos sold 1,489 shares of common stock at a price of $26.7844 per share.
• This sale was to cover tax withholding obligations related to the vesting and settlement of RSUs, described as a 'sell to cover' transaction.
• Following these transactions, Piekos beneficially owns 21,661 shares of common stock directly, and a total of 55,000 shares indirectly through RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions are standard insider equity compensation and tax-related sales, not indicative of significant positive or negative company performance.

Positives

• The acquisition of 5,000 RSUs indicates continued equity-based compensation for the CFO.
• The 'sell to cover' transaction for tax withholding is a standard procedure and does not necessarily reflect a discretionary sale of shares by the CFO.

Negatives

• A sale of 1,489 shares occurred, although it was for tax withholding purposes.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. These transactions are standard for executive compensation and tax management.

Stakeholder Impact

• Shareholders: The transactions are routine and do not suggest a change in the CFO's confidence in the company's prospects, as the sale was for tax purposes.
• Employees: The RSU vesting schedule is part of the company's employee compensation strategy.
• Management: The CFO is managing their equity compensation and associated tax liabilities.

Next Steps

• Continued vesting of RSUs on a quarterly anniversary basis as per the plan.
• Future transactions will be reported on subsequent Form 4 filings as required.

Key Dates

Keywords

KalVista Pharmaceuticals, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, Common Stock, Tax Withholding, Brian Piekos, Chief Financial Officer